SWOT Analysis for Monte Rosa Therapeutics Inc

Significant (over 30%) distance from 52 week high
Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Company with Low Debt
Increasing Revenue every quarter for the past 3 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Increasing profits every quarter for the past 4 quarters
Stock with Low PE (PE < = 10)
Volume Shockers

Stocks with Quarter Change % less than Industry
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Biggest Price Losers from Open
High volume, top losers
Top Losers
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter